ClinicalTrials.gg
CompletedNCT01874054Updated Feb 12, 2019Results posted

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

A Phase 1/2 interventional study of brentuximab vedotin and bendamustine in Hodgkin Disease, sponsored by Seagen Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-12.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
38th of 80
55 · median 52
Started
2013
with 9 others
Phase 1/2
12 of 80
none open now
Registered
22nd of 80
by date
Lead sponsor
12 of 80
Seagen Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 38th largest by enrollment, is one of 10 that started in 2013, is one of 12 in phase 1/2, and was the 22nd registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine the recommended dose level of bendamustine in combination with brentuximab vedotin. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.

03

Conditions studied

  • Hodgkin Disease

Keywords

  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Hodgkin Disease
  • Hematologic Diseases
  • Drug Therapy
  • Immunotherapy
  • Antigens, CD30
  • Lymphoma
  • monomethylauristatin E
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathological diagnosis of classical Hodgkin lymphoma
  • Failed standard front-line therapy
  • of at least 1.5 cm as documented by radiographic technique
  • performance status less than or equal to 2

Exclusion criteria

Exclusion Criteria:

  • Received prior salvage therapy, including radiotherapy
  • Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drug
  • Concurrent use of other agents
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Brentuximab Vedotin + Bendamustine

    Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles

    Drug: brentuximab vedotin · Drug: bendamustine

Interventions

  • 1.8 mg/kg every 3 weeks by intravenous (IV) infusion

    Also known as: Adcetris; SGN-35

  • 90 mg/m2 on Days 1 and 2 of 3-week cycles

06

What researchers measure

Primary outcomes

  1. Complete Remission Rate

    Complete remission rate among all subjects (Phase 1 and 2 combined) treated at the dose level selected for Phase 2. Complete remission (CR) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma is a disappearance of all evidence of disease.

    Time frame: Up to 4.6 months

  2. Incidence of Adverse Events (AEs)

    All AEs reported after initiation of treatment and pre-existing conditions that worsen after initiation of treatment will be considered treatment-emergent AEs (TEAEs). All AEs will be coded by system organ class, MedDRA preferred term, and severity grade using NCI CTCAE V4.03. All recorded AEs will be included in the data listings.

    Time frame: Up to 13.8 months

Secondary outcomes

  1. Incidence of Dose-limiting Toxicities

    Incidence of dose-limiting toxicity (DLT) was evaluated in an initial safety cohort of 10 patients who were followed for protocol-defined DLT events until Cycle 2 Day 1.

    Time frame: Up to 3 weeks; first cycle of therapy through the first day of Cycle 2

  2. Overall Best Response Rate

    Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease), partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites), stable disease (SD, failure to obtain a complete or partial response or progressive disease), or progressive disease (PD, any new lesion or increase by 50% or more of previously involved sites from nadir) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma

    Time frame: Up to 4.6 months

  3. Duration of Response

    The time from first observation of remission to disease progression/relapse or death from any cause, whichever occurs first.

    Time frame: Up to 47.8 months

  4. Progression-free Survival

    The time from first dose of study medication to first documentation of disease progression/relapse, or to death due to any cause, whichever occurs first.

    Time frame: Up to 49 months

07

Results

Posted Apr 6, 2017

Participant flow

June 2013 - July 2016

Participant flow — Overall Study
MilestoneBrentuximab Vedotin + Bendamustine
Started55
Completed ≥2 cycles of combo treatment53
Completed 16 cycles of bv treatment17
Completed0
Not completed55
Withdrew: Withdrawal by subject3
Withdrew: Study termination by sponsor42
Withdrew: Lost to follow-up5
Withdrew: Death5

Outcome measures

PrimaryComplete Remission Rate

Complete remission rate among all subjects (Phase 1 and 2 combined) treated at the dose level selected for Phase 2. Complete remission (CR) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma is a disappearance of all evidence of disease.

Time frame:
Up to 4.6 months
Reported as:
Number · percentage of participants
Complete Remission Rate
percentage of participantsBrentuximab Vedotin + Bendamustine
Complete Remission Rate73.6 (59.67 to 84.74)
PrimaryIncidence of Adverse Events (AEs)

All AEs reported after initiation of treatment and pre-existing conditions that worsen after initiation of treatment will be considered treatment-emergent AEs (TEAEs). All AEs will be coded by system organ class, MedDRA preferred term, and severity grade using NCI CTCAE V4.03. All recorded AEs will be included in the data listings.

Time frame:
Up to 13.8 months
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs)
ParticipantsBrentuximab Vedotin + Bendamustine
Any Treatment-Emergent Adverse Event (TEAE)55
Any TEAE with Severity >= Grade 331
Any Treatment-Related Adverse Event54
Any Serious Adverse Event18
Any Treatment-Related Serious Adverse Event15
Treatment Discontinuation Due to Adverse Event20
SecondaryIncidence of Dose-limiting Toxicities

Incidence of dose-limiting toxicity (DLT) was evaluated in an initial safety cohort of 10 patients who were followed for protocol-defined DLT events until Cycle 2 Day 1.

Time frame:
Up to 3 weeks; first cycle of therapy through the first day of Cycle 2
Reported as:
Count of participants · Participants
Incidence of Dose-limiting Toxicities
ParticipantsBrentuximab Vedotin + Bendamustine
Incidence of Dose-limiting Toxicities0
SecondaryOverall Best Response Rate

Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease), partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites), stable disease (SD, failure to obtain a complete or partial response or progressive disease), or progressive disease (PD, any new lesion or increase by 50% or more of previously involved sites from nadir) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma

Time frame:
Up to 4.6 months
Reported as:
Count of participants · Participants
Overall Best Response Rate
ParticipantsBrentuximab Vedotin + Bendamustine
Complete Remission39
Partial Remission10
Stable Disease3
Progressive Disease1
SecondaryDuration of Response

The time from first observation of remission to disease progression/relapse or death from any cause, whichever occurs first.

Time frame:
Up to 47.8 months
Reported as:
Median · months
Duration of Response
monthsBrentuximab Vedotin + Bendamustine
Duration of Response43.0 (18.7 to 47.8)
SecondaryProgression-free Survival

The time from first dose of study medication to first documentation of disease progression/relapse, or to death due to any cause, whichever occurs first.

Time frame:
Up to 49 months
Reported as:
Median · months
Progression-free Survival
monthsBrentuximab Vedotin + Bendamustine
Progression-free Survival44.2 (20.9 to 49.0)

Adverse events

Collected over Up to 13.8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin + Bendamustine5/55 (9.1%)18/55 (32.7%)55/55 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventBrentuximab Vedotin + Bendamustine
PyrexiaGeneral disorders8/55
HypotensionVascular disorders5/55
ChillsGeneral disorders3/55
MalaiseGeneral disorders2/55
DiarrhoeaGastrointestinal disorders2/55
NauseaGastrointestinal disorders2/55
VomitingGastrointestinal disorders2/55
Rash maculo-papularSkin and subcutaneous tissue disorders2/55
UrticariaSkin and subcutaneous tissue disorders2/55
Febrile neutropeniaBlood and lymphatic system disorders2/55
Most frequent other events
Showing 10 of 70
Most frequent other events
EventBrentuximab Vedotin + Bendamustine
NauseaGastrointestinal disorders40/55
FatigueGeneral disorders30/55
DiarrhoeaGastrointestinal disorders20/55
VomitingGastrointestinal disorders20/55
ConstipationGastrointestinal disorders17/55
ChillsGeneral disorders15/55
PyrexiaGeneral disorders15/55
AlopeciaSkin and subcutaneous tissue disorders14/55
RashSkin and subcutaneous tissue disorders14/55
Peripheral sensory neuropathyNervous system disorders14/55

Baseline characteristics

All subjects who enrolled and received at least 1 dose of brentuximab vedotin.

Age, Categorical
Age, Categorical(Participants)Brentuximab Vedotin + Bendamustine
<=18 years0
Between 18 and 65 years50
>=65 years5
Age, Continuous
Age, Continuous(years)Brentuximab Vedotin + Bendamustine
Median36 (19 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin + Bendamustine
Female31
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brentuximab Vedotin + Bendamustine
Hispanic or Latino3
Not Hispanic or Latino51
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brentuximab Vedotin + Bendamustine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American6
White46
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)Brentuximab Vedotin + Bendamustine
United States55
Eastern Cooperative Group Oncology Performance Status
Eastern Cooperative Group Oncology Performance Status(Participants)Brentuximab Vedotin + Bendamustine
031
123
21
08

Study locations

13 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Pacific Hematology Oncology Associates
    San Francisco, California 94115, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Oncology Institute of Hope & Innovation, The
    Whittier, California 90603, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic Minnesota
    Rochester, Minnesota 55905, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-7680, United States
  • Columbia University Medical Center
    New York, New York 10022, United States
  • Jewish Hospital, The
    Cincinnati, Ohio 45236, United States
  • Case Western Reserve University / University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Saint Francis Hospital / Bon Secours
    Greenville, South Carolina 29601, United States
  • Charles A. Sammons Cancer Center / Baylor University Medical Center
    Dallas, Texas 75246, United States
09

References and documents

Publications

  • LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27. PubMed 29703778 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Dec 2015 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2013
First posted
Jun 10, 2013
Start
Jun 2013
Primary completionActual
Dec 2015
CompletionActual
Feb 20, 2018
Results first posted
Apr 6, 2017
Last update
Feb 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01874054
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Jun 10, 2013
Start date
Jun 2013
Primary completion
Dec 2015
Completion
Feb 20, 2018
Results posted
Apr 6, 2017
Last update
Feb 12, 2019

Study contacts

Neil Josephson, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Bendamustine

Start the discussion